OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedHealthfirstPolicy PO-RE-066v5

Prescription Medication and Illicit Drug Testing in the Outpatient Setting

Customize your policy alerts

Sign up for Healthfirst Policy PO-RE-066v5 alerts

Get alerted when Policy PO-RE-066v5 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines coverage criteria, limitations, and documentation/reimbursement rules for outpatient presumptive and definitive drug testing (primarily urine/oral fluid) for clinical purposes; applies to Healthfirst members and outpatient providers in North Carolina. This part covers indications, specimen types, frequency limits, and prohibited testing practices.

Policy Summary

PayerHealthfirst

PolicyPrescription Medication and Illicit Drug Testing in the Outpatient Setting

Policy CodePolicy PO-RE-066v5

Change TypeMaterial coverage clarification + coding updates

Effective DateJul 1, 2025

Last ReviewMay 19, 2025

Next Review DateN/A

Key ActionVerify member benefits prior to ordering drug testing and document medical necessity in the record.

SourceLink

POLICY UPDATE CHANGES

Added new 'General' section and new CC6 stating that presumptive drug screening and definitive drug testing do not meet coverage criteria in situations not addressed elsewhere.

Added CPT codes 0517U, 0518U, 0519U, 0520U (effective 10/1/2024) as coding modifications.

Removed former C and E in disclaimer within section III and adjusted numeric formatting (CC1 and CC2) to written words for consistency.

Updated the background, guidelines and recommendations, and evidence-based scientific references without changing coverage criteria.

up to 4max presumptive tests/yr (high risk)

≤7definitive testing allowed (classes)

1–2/weekrecommended random UDT (0–90 days)

urine/oral fluidprimary covered specimens

4CPT codes added

Coverage Criteria for Presumptive and Definitive Drug Testing

Presumptive Urine Drug Screening — Covered Indications

Presumptive urine drug screening MEETS COVERAGE when ANY of the following apply:

Presumptive urine coverage: a. Assess individuals treated for chronic non-cancer pain when clinical evaluation (history/signs/symptoms) suggests use of non-prescribed medications or illegal substances; includes prior to initiating chronic opioid therapy and routine monitoring for those on opioid therapy with frequency based on risk level and documented history; testing at visit for aberrant behavior meets criteria.

Random testing interval and drug selection must be based on history and documented in the medical record.

Pregnancy: b. Pregnant individuals at high risk for substance abuse when suspicion exists based on screening questions or PDMP data, documented in the record.

Obtain informed consent and consider validated verbal screening tools per ACOG guidance.

Newborns: c. Newborns when there is a history of maternal substance abuse or agitated/altered mental status in the birthing parent.

Policy Summary

PayerHealthfirst

PolicyPrescription Medication and Illicit Drug Testing in the Outpatient Setting

Policy CodePolicy PO-RE-066v5

Change TypeMaterial coverage clarification + coding updates

Effective DateJul 1, 2025

Last ReviewMay 19, 2025

Next Review DateN/A

Key ActionVerify member benefits prior to ordering drug testing and document medical necessity in the record.

SourceLink

On This Page

Document maternal history or clinical concerns in the record.

Transplant candidates: d. Organ transplant candidates with a history of substance abuse to demonstrate abstinence prior to transplant.

Testing should be documented as part of pre-transplant evaluation.

Mental illness or behavioral disorders: e. Individuals with suspected or diagnosed mental illness (including SUD) or with ADHD/disruptive behavior disorders when substance use is suspected.

Use testing to inform diagnosis/management in context of clinical assessment.

Cancer/epilepsy patients: f. Cancer patients receiving opioid pain medication and individuals with epilepsy when testing may affect safety (e.g., drug interactions) or management.

Consider drug interactions (e.g., cocaine with antiepileptics) as rationale for testing.

Substance use treatment monitoring: g. Individuals in treatment for substance use disorder: random qualitative testing after baseline — 0–90 days abstinence: 1–2 per week; >90 days abstinence: 1–3 per month.0–90 days: 1–2/week; >90 days: 1–3/month

Frequencies must be documented in the patient medical record.

Differential diagnosis: h. Individuals where substance abuse is in the differential diagnosis of the presenting condition.

Use testing alongside clinical assessment to guide evaluation.

Definitive Drug Testing — Covered Indications

Definitive/confirmatory testing MEETS COVERAGE when ALL of the following are met:

Definitive testing general: Laboratory-based definitive drug testing is specifically requested with documented rationale by the treating physician and is limited to panels of up to seven drug classes.≤7 drug classes

Documentation of medical necessity required in the patient's record.

Triggers for definitive testing: a. Presumptive test result is inconsistent with the patient's history, clinical presentation, or statement (e.g., negative for prescribed meds or unexpected positive for unprescribed/illegal drug); b. For diagnosing or monitoring individuals with substance use disorder when accurate, reliable results are necessary for treatment decisions with frequency limits by abstinence duration (0–30 days: ≤1/week; 31–90 days: 1–3/month, max 3/month; >90 days: 1–3 every three months, max 3/3 months); c. Monitoring individuals on opioid therapy; d. When no adequate presumptive test exists for the specific drug/metabolite; e. To definitively identify specific drugs within a drug family; f. When a definitive concentration is needed to guide management.frequency limits specified

Each condition supports coverage when the overall 'all' requirement (documented rationale and ≤7 classes) is met.

Use of definitive vs presumptive testing

Covered when meeting clinical justification for accurate identification or monitoring:

Definitive testing recommended: Use definitive UDM testing (GC‑MS, LC‑MS, or LC‑MS/MS) as the most accurate method for baseline assessment and ongoing monitoring in most chronic pain patients being considered for or receiving opioids, unless institutional or payer policy requires presumptive testing.

Consensus recommendation (Argoff et al. 2018) — definitive testing preferred for accuracy and confirmation.

Monitoring frequency by risk level

Perform UDM at the following minimum frequencies:

UDM frequency recommendations: Perform baseline UDM prior to initiation of opioid therapy. During ongoing monitoring: low‑risk — at least annually; moderate‑risk — two or more times per year; high‑risk — three or more times per year. Additional monitoring may be performed as clinically indicated.low=annual; moderate=≥2/year; high=≥3/year

Frequencies reflect consensus recommendations (Argoff et al., AMDG) and should be individualized by clinical judgment.

Clinical scenarios where testing may inform management

Testing may be useful in specific situations:

Use cases: Drug testing may inform management for: drug‑treatment programs; pain management (including baseline risk assessment and monitoring); psychiatric evaluation when substance use could underlie or exacerbate symptoms (including acute psychosis); pre‑procedural screening for surgeries such as joint arthroplasty; assessment prior to beta‑blocker administration or when interactions with antiepileptic drugs are possible; and when hair testing or alternate matrices complement urine testing for specific detection windows.

Evidence and observational studies support selective use in these scenarios rather than universal screening.

Risk-stratified UDT frequency and monitoring

Covered/appropriate when meeting risk-based monitoring and clinical judgment criteria

Baseline and ongoing monitoring

Risk‑stratified frequency: Low‑risk: at least annually (or every 6–12 months per AAFP); Moderate‑risk: 2 or more times per year (or every 3–6 months per AAFP); High‑risk: 3 or more times per year (or every 1–3 months per AAFP/AMDG guidance).low=annual; moderate=2+; high=3+
Frequencies vary by guideline; apply clinical judgment.

Testing modality and confirmation

Use of definitive vs presumptive testing

Preferred testing methods: Definitive testing (GC‑MS/LC‑MS/MS) is preferred for baseline assessment and confirmation of unexpected results or when specific substance identification or quantification will affect major clinical decisions.definitive preferred

AACC and Argoff consensus recommend definitive testing for accuracy and confirmation.

When presumptive testing acceptable: Immunoassays (POC or lab) may be acceptable for low‑risk monitoring or when required by payer/institutional policy; clinicians must understand assay limitations and consult laboratory information when interpreting results.presumptive acceptable in low‑risk or payer‑mandated situations

CDC, AACC acknowledge immunoassay use with caveats; confirm unexpected results with definitive methods.

Testing frequency by patient risk

Testing frequency guidance from cited organizations (expressed as ranges and context-specific recommendations):

Risk-based UDT frequency: Guideline-reported ranges: Low‑risk — up to once per year; Moderate‑risk — up to 2–4 times per year (varies by source); High‑risk — 3–4 per year or more frequent/random testing (including monthly or at every visit/refill in some guidance).frequency ranges

Sources include Washington State AMDG, ASAM, Texas Pain Society, SAMHSA; frequencies differ by context and setting.

Modality and confirmatory testing

Guidance on test modality and confirmatory testing:

Modality and confirmatory testing: Use presumptive immunoassay testing as a routine screening tool but perform definitive testing (GC‑MS or LC‑MS) when specific substances must be identified, quantification is clinically necessary, or major clinical/legal decisions depend on the result.

ASAM and SAMHSA recommend definitive testing to confirm unexpected or consequential results and when results will inform major clinical decisions.

Specimen types and mandated analytes

Specimen types and mandated analytes in federal guidance:

Specimen matrices and required analytes: Urine is the most common validated matrix; other matrices include blood, oral fluid, breath, sweat, and hair. HHS federal workplace guidelines require testing each specimen for marijuana and cocaine and authorize additional Schedule I/II drugs or validity tests as appropriate.

Consider matrix suitability and regulatory requirements when selecting specimen type; oral fluid testing has specific HHS rules.

Coverage stance and clinically appropriate use

Key coverage stance and clinical-use considerations from the document

Coverage limitation: In all other situations not addressed above, presumptive drug screening and definitive drug testing DO NOT MEET COVERAGE CRITERIA.

Added as a general default non‑coverage statement in the policy revision history.

Clinical situations where testing may be considered: Urine testing may provide useful information during initial psychiatric evaluation or in emergency cases of suspected intoxication/overdose; WHO suggests urine testing when the person cannot convey ingestion history and occasional testing to confirm non‑use may be considered.

Contextual recommendations from WHO and clinical societies; interpret tests in clinical context and confirm as appropriate.

Testing practice requirements: When testing is performed, obtain informed consent where indicated, use validated screening tools (e.g., per ACOG for obstetric populations), and request confirmatory testing with mass spectrometry/GC or LC chromatography as appropriate due to limitations of presumptive UDT.

Reflects ACOG and other guidance on consent and confirmatory testing.

General - Default non-coverage

Policy-level clarification added:

CC6 General default non-coverage: In all other situations not addressed above, presumptive drug screening and definitive drug testing DO NOT MEET COVERAGE CRITERIA.

Added to establish default non‑coverage for situations not specifically enumerated in the policy.

Definitive drug testing panels that exceed 7 drug classes do not meet coverage criteria; similarly, testing using proprietary panels (for example, CareView360) is not covered. Specimen validity testing (such as urine specific gravity, creatinine, pH, oxidant level, or genetic identity testing) is expressly excluded from coverage. Providers should plan testing within the policy limits (≤7 classes for definitive tests) and avoid ordering proprietary or specimen‑validity assays that will likely be denied or not reimbursed.

Operational notes: only urine or oral fluid specimens are generally covered (blood covered only for anuric chronic renal failure), and confirmatory/definitive testing must be supported by documentation of clinical rationale in the patient’s medical record. Same‑day duplicate testing of the same analyte from different specimens and blanket or standing orders for all patients are not reimbursed.

For most acute clinical encounters, routine drug‑of‑abuse (DOA) monitoring has limited value and may be unnecessary. Evidence cited in the policy indicates DOA testing is most useful in specific settings (for example, drug‑treatment programs, pain management, or psychiatric evaluation) rather than as a blanket screen in acute care. Large retrospective and other studies referenced found limited utility of routine screening in many acute settings, and some routine screens may be wasteful.

When DOA testing is considered in acute contexts, it should be targeted to situations where results would meaningfully change management (e.g., unexplained acute psychosis, pre‑administration checks with drug interactions, seizure evaluation), not performed as routine screening for all patients.

Quantitative definitive urine testing should not be used routinely to evaluate dose adjustments or to assess adherence to a prescribed dosing regimen. The AACC and related guidance indicate that quantitative definitive testing is not generally more useful than qualitative definitive testing for routine outcomes in pain management and should be reserved for complex cases (for example, suspected variant metabolism, spiked samples, multiple opioids, or to rule out alternative exposure sources).

When precise concentrations are clinically necessary (rare, complex scenarios), quantitative definitive testing can be justified, but routine dosing or adherence decisions should not rely on quantitative urine levels alone.

Guidelines do not reach uniform agreement on routine urine drug testing: some organizations recommend testing only for high‑risk patients, others (for example, certain workers’ compensation programs) may require mandatory UDT, and many recommend weighing pros and cons based on clinical context. Clinicians should apply guideline recommendations and local regulatory requirements and document the rationale when electing to test.

Routine or universal urine drug testing in pregnancy is controversial. ACOG recommends using validated verbal screening tools (for example, 4Ps, NIDA Quick Screen, CRAFFT) rather than routine UDT and emphasizes informed consent and compliance with state law. When testing is performed in obstetric care, providers must understand test limitations and request confirmatory mass‑spectrometry testing as appropriate.

This policy clarifies that situations not specifically addressed in the coverage criteria are excluded: presumptive and definitive drug testing for unenumerated indications do not meet coverage criteria. Definitive testing for panels >7 drug classes, proprietary tests, and specimen validity testing are explicit examples of non‑covered situations.

Providers should verify coverage against member benefits and applicable state/federal rules before ordering tests outside the listed covered indications, as such orders may be denied.

Reiteration of policy default: unless an indication is specifically listed as covered, presumptive drug screening and definitive drug testing do not meet coverage criteria. Routine blanket orders or standing orders for all patients are not reimbursed, and providers should avoid ordering tests without documented medical necessity.

Psychiatric pre‑administration screening for acetaminophen or salicylates was evaluated in a large multicenter retrospective VA study and was found to be unnecessary and wasteful. This supports the policy stance that routine, untargeted toxicology screening in psychiatric pre‑administration settings is not routinely indicated.

Routine quantitative definitive urine testing for the purpose of evaluating medication dosage or general adherence is not generally useful and is therefore not covered for routine monitoring. Definitive (qualitative) testing is preferred for confirmation of unexpected results or when specific identification will change management; quantitative testing is reserved for specialized or complex clinical questions.

Clinical guidelines vary in their endorsement of routine or universal testing: some recommend testing only for higher‑risk patients while others provide more prescriptive frequencies or requirements. Consensus documents recommend baseline testing and risk‑stratified periodic monitoring rather than universal routine testing; apply clinical judgment and document decisions in the medical record.

Policy restatement: testing not specifically listed as covered is not covered. The recently added General section formalizes this default non‑coverage position—providers must ensure testing aligns with one of the enumerated covered indications and is documented appropriately to support reimbursement.

Additional operational note: per the policy addendum and revision history, presumptive and definitive testing for any situations not enumerated in the policy do not meet coverage criteria. This reiteration reinforces that unenumerated uses are excluded and may be denied.

Coding and Reimbursement Codes

Not reimbursed codes/claimsmixedNot Covered

Any AMA definitive drug class codes

Specifically listed as not reimbursed

Not reimbursed - same-day duplicate testingmixedNot Covered

Same-day duplicate testing

Same day testing of the same drug or metabolites from two different samples (e.g., both a blood and a urine specimen) is not reimbursed

Presumptive and combined presumptive/confirmation CPTCPT

80305	Drug test(s), presumptive, any number of drug classes; direct optical observation (eg, immunoassay)
80306	Drug test(s), presumptive, any number of drug classes; instrument assisted direct optical observation (eg, immunoassay)
80307	Drug test(s), presumptive, any number of drug classes; instrument chemistry analyzers, chromatography, and mass spectrometry
0007U	Drug test(s), presumptive, with definitive confirmation of positive results, urine, includes specimen verification

Proprietary and newer CPT II/III codes (selected)CPT

0011U	Prescription drug monitoring, LC-MS/MS, oral fluid, reported vs estimated steady-state range
0051U	Prescription drug monitoring, LC-MS/MS, urine, 31 drug panel, quantitative
0054U	Prescription drug monitoring, 14+ classes, definitive tandem MS with chromatography, capillary blood, quantitative
0079U	Comparative DNA analysis using selected SNPs, urine and buccal DNA, for specimen identity verification
0082U	Drug test(s), definitive, 90+ drugs, definitive chromatography with mass spectrometry, plus presumptive immunoassay
0093U	Prescription drug monitoring, evaluation of 65 common drugs by LC-MS/MS, urine
0227U	Drug assay, presumptive, 30 or more drugs or metabolites

Definitive and therapeutic monitoring codes (CPT/HCPCS/G-codes)mixed

0328U	Drug assay, definitive, 120+ drugs and metabolites, urine, quantitative LC-MS/MS
0517U	Therapeutic drug monitoring, 80+ psychoactive drugs, LC-MS/MS, plasma, qualitative and quantitative
0518U	Therapeutic drug monitoring, 90+ pain and mental health drugs, LC-MS/MS, plasma, qualitative and quantitative
0519U	Therapeutic drug monitoring, medications specific to pain, depression, anxiety, LC-MS/MS, plasma, 110+ drugs
0520U	Therapeutic drug monitoring, 200+ drugs or substances, LC-MS/MS, plasma, qualitative and quantitative
G0480	Drug test(s), definitive, GC/MS or LC/MS methods, specimen validity testing, 1-7 drug classes
G0481	Drug test(s), definitive, GC/MS or LC/MS methods, specimen validity testing, 8-14 drug classes
G0482	Drug test(s), definitive, GC/MS or LC/MS methods, specimen validity testing, 15-21 drug classes
G0483	Drug test(s), definitive, GC/MS or LC/MS methods, specimen validity testing, 22+ drug classes
G0659	Drug test(s), definitive, performed without method- or drug-specific calibration or matrix-matched QC; any number of drug classes

Recently added CPT CodesCPT

0517U	CPT - code added via off-cycle modification (effective 10/1/2024)
0518U	CPT - code added via off-cycle modification (effective 10/1/2024)
0519U	CPT - code added via off-cycle modification (effective 10/1/2024)
0520U	CPT - code added via off-cycle modification (effective 10/1/2024)

inv-30: Definitive drug class panel size — coverage threshold

Definitive panel size thresholdDefinitive/confirmatory laboratory-based drug testing is covered for panels of up to 7 drug classes; panels larger than 7 drug classes DO NOT MEET COVERAGE.

Documentation requirement for covered panelsDefinitive testing for ≤7 classes must be specifically requested with documented rationale by the treating physician.

Proprietary test exclusionDefinitive or presumptive testing using proprietary panels (e.g., CareView360) is not covered regardless of panel size.

inv-31: Assay cutoff concentrations — documented thresholds for selected analytes

Morphine (opioid) cutoffMorphine urinary cutoff adjusted by SAMHSA from 300 ng/mL to 2000 ng/mL to reduce poppy-seed false positives.

Amphetamine / Methamphetamine cutoffs (DRI assay)Amphetamine cutoff 500 ng/mL; Methamphetamine cutoff 1000 ng/mL (DRI® Amphetamines Assay).

Cocaine metabolite (benzoylecgonine) cutoffDRI Cocaine Metabolite Assay reported concentration cutoff ~150–300 ng/mL for benzoylecgonine in urine.

inv-32: Drug class count thresholds — G0480..G0483 mapping to class count ranges

G0480 mappingG0480 — Definitive drug test(s), GC/MS or LC/MS methods, specimen validity testing: 1–7 drug classes.

G0481 mappingG0481 — Definitive drug test(s), GC/MS or LC/MS methods, specimen validity testing: 8–14 drug classes.

G0482 mappingG0482 — Definitive drug test(s), GC/MS or LC/MS methods, specimen validity testing: 15–21 drug classes.

G0483 mappingG0483 — Definitive drug test(s), GC/MS or LC/MS methods, specimen validity testing: 22+ drug classes.

Provider Responsibilities, Documentation, and Billing Guidance

Documentation Required

Benefit verification required

Verify member benefits and applicable rules before ordering/testing. Coverage depends on the member's benefit plan, and Medicare/Medicaid specifications may impose additional requirements. Confirm whether the requested presumptive or definitive drug testing is a covered service for the member and obtain any required prior authorization per payer rules before performing testing.

Benefit verification required prior to testing
Coverage depends on evidence of coverage and state/federal rules

Step Therapy

Step therapy

No formal step therapy rules for drug testing are specified in this excerpt. Use clinical judgment and follow payer/institutional requirements when selecting testing modalities.

No step therapy specified in policy excerpt

Prior Authorization

When to obtain definitive confirmatory testing

Obtain definitive (confirmatory) testing when presumptive or immunoassay results are unexpected or will influence consequential clinical or non-clinical decisions (for example, before stopping or initiating opioids, taking disciplinary or legal actions, or when results are inconsistent with clinical expectations). Document clinical rationale for confirmatory testing in the medical record.

Definitive testing recommended for unexpected/incongruent results
Confirmatory testing should be supported by documentation of rationale

Note

HHS oral fluid testing and allowed additional testing

HHS allows oral fluid testing where federal workplace testing applies and authorizes additional drug and specimen validity testing on oral fluid on a case-by-case basis (including testing for marijuana and cocaine and other Schedule I/II drugs per panel). MRO-requested validity testing and biomarker tests may be permitted; abnormal specimens may warrant additional testing. Ensure compliance with HHS requirements when using oral fluid specimens.

Oral fluid specimens must be tested for marijuana and cocaine per HHS panel
HHS permits additional drug/validity/biomarker testing on oral fluid on a case-by-case/MRO request

Billing Rule

Procedure codes listed — verify coding and authorization

Verify appropriate procedure codes when ordering and billing. Use the listed presumptive and definitive CPT/HCPCS/CPT-unique codes and ensure correct code selection, modifier use, and prior authorization as required by the payer. Off-cycle/additional CPT codes added (0517U–0520U and other proprietary codes) must be used correctly.

Common presumptive codes: 80305, 80306, 80307
Definitive and proprietary codes: 0007U, 0011U, 0051U, 0054U, 0079U, 0082U, 0520U, G0480, and others listed
Added CPT codes 0517U–0520U (off-cycle coding update)

Denial Risk

Failure to perform urine drug screening

For worker's compensation or states with specific rules, failure to perform urine drug screening prior to initiating chronic opioid therapy (where required) may conflict with state WC guidelines and could affect care decisions. Perform required pre-treatment UDS when mandated by applicable WC or state rules.

UDS before starting chronic opioid therapy is required/recommended in some WC programs (e.g., Wisconsin)
Failure to perform may conflict with state worker's compensation guidance

Documentation Required

When used, UDT results and patient education

When used for monitoring, document how UDT results were used in clinical care and provide patient education about testing purpose, interpretation limits, and implications. Include counseling, follow-up plans, and any behavior-change interventions resulting from results.

Document use of UDT results in monitoring programs and patient education provided
Educate patients that UDTs have limitations and are one part of clinical assessment

Documentation Required

Document comprehensive screening and risk assessment

Document comprehensive screening and risk assessment before and during opioid therapy: include screening tools, full history, PDMP query, urine toxicology results (when performed), risk stratification, treatment goals, opioid agreements, and referrals when high risk. Ensure documentation supports medical necessity for testing.

Record screening, history, PDMP query, UDT results, risk stratification, and treatment goals
Refer to specialists for high-risk patients per recommendations

Documentation Required

Consent and confirmatory testing

Obtain informed consent when appropriate and be aware of test characteristics and limitations. For unexpected or consequential immunoassay results, request confirmatory testing with mass spectrometry (GC-MS, LC-MS/MS) or other definitive methods. Record consent, test choice, and confirmation rationale in the medical record.

Obtain patient consent where required and document it
Request mass-spec confirmation for unexpected or consequential results

Note

Determination basis

Reimbursement and coverage determinations are based on applicable evidence of coverage, state and federal regulations, provider agreements, and adherence to this policy and coding/billing rules. Failure to follow coding, billing, and reimbursement guidelines may result in claim denials or recoupment.

Coverage decisions rely on member EOC and state/federal rules
Noncompliance with coding/billing policies may lead to denial/recoupment

Note

Initial POC immunoassay then confirm as needed

Algorithmic testing approach: consider initial point-of-care (POC) or laboratory immunoassay presumptive testing for baseline and monitoring. If results are inconsistent with expectations or clinically significant, follow with definitive confirmatory testing (GC-MS, LC-MS/MS) per guidance and document the rationale.

Initial POC/lab immunoassay for baseline screening and monitoring
Use definitive confirmatory testing when indicated

Level-of-Care Specific Criteria

Outpatient substance use treatment/monitoring

Outpatient substance use treatment/monitoring: Definitive testing may be used for diagnosis/monitoring of individuals with substance use disorder when accurate, reliable results are necessary; random qualitative testing frequencies after baseline: 0–90 days: 1–2/week; >90 days: 1–3/month.see definitive testing frequencies

Document rationale and results in the medical record.

Outpatient

Outpatient: Perform baseline UDM for patients being considered for opioid therapy or in drug treatment programs, or when clinical suspicion of recent substance use exists; ongoing monitoring frequency based on risk: annual (low), ≥2/year (moderate), ≥3/year (high).

Document assessment, PDMP checks, and monitoring plan in the chart.

Opioid Treatment Program / Substance Use Disorder treatment

OTP admission testing: Test for opioids/methadone, amphetamines, cocaine, and benzodiazepines at minimum prior to admission to an Opioid Treatment Program; include additional drugs based on community patterns or individual indications.

SAMHSA recommends these minimum analytes for OTP admission; document results.

Outpatient

Outpatient emergency indications: Perform urine drug screen when intoxication, withdrawal, or overdose is suspected, especially if the patient cannot report ingestion; use results to inform immediate management and consider confirmatory testing for consequential findings.

WHO recommends UDT in emergency cases when patient history is unavailable.

Treatment Modalities and Monitoring Programs

Medication-assisted monitoring / Opioid therapy monitoring

Medication-assisted monitoring / Opioid therapy monitoring: Presumptive and/or definitive testing may be used to monitor adherence and detect non‑prescribed opioids; frequency after initiation varies by risk level (low ~1/yr, moderate ~2/yr, high up to 4/yr) with aberrant behaviors prompting testing at visit.

Random testing interval and selected drugs must be based on history and documented.

UDM (Urine Drug Monitoring)

UDM framework: Prefer definitive testing (LC‑MS/MS) for baseline and ongoing monitoring in chronic pain patients; immunoassays may be acceptable for low‑risk patients or when required by payer/institutional policies.

Argoff consensus supports definitive testing as most accurate; document testing approach.

Medication monitoring and OUD linkage

Use of UDT in treatment planning: Use unexpected UDT results to optimize pain management, consider naloxone where appropriate, and offer or refer to medications for opioid use disorder when indicated; integrate results with PDMP and clinical assessment.clinician judgment

CDC and ASIPP recommend using results to improve patient safety and linkage to treatment rather than punitive measures.

Toxicology testing (presumptive and definitive)

Toxicology testing scope: Presumptive immunoassays are appropriate for screening; definitive testing (GC‑MS/LC‑MS) should be used to confirm unexpected or clinically consequential results and when specific identification/quantification is needed.

ASAM and SAMHSA recommend definitive testing for confirmation and major clinical decisions.

Screening and monitoring

Screening and monitoring approaches: Toxicology testing should be used when clinically indicated (intake, admission, during treatment) and in conjunction with self‑report and clinical assessment; random, unannounced testing is preferred over scheduled testing by several societies.

OASAS and ASAM guidance emphasize clinical integration and appropriate panel selection.

Toxicology use in addiction treatment

Guidance sources: References include ASAM white paper, SAMHSA mandatory guidelines, OASAS guidance on toxicology use in certified programs, and AATOD/ASIPP resources relevant to toxicology and treatment programs.

These sources inform clinical practice but do not alone define coverage; follow documentation and payer rules.

Definitions and Test Methodology

inv-58: Presumptive drug screening — immunoassay-based qualitative/semi-quantitative testing definition

DefinitionPresumptive drug screening: immunoassay-based qualitative or semi-quantitative testing used to identify use or non-use of a drug or drug class (rapid screening, detects classes rather than specific drugs).

Typical use caseUsed as an initial screen in-office or in the laboratory to detect the presence of drug classes and to inform whether confirmatory testing is needed.

Performance caveatImmunoassays are prone to cross-reactivity and lower sensitivity compared with MS-based definitive methods; package inserts and lab consultation are recommended for interpretation.

inv-59: Definitive drug testing — chromatography and mass spectrometry–based methods definition

DefinitionDefinitive drug testing: chromatographic and mass spectrometry–based methods (e.g., GC, LC with tandem MS) that identify specific drugs and metabolites qualitatively or quantitatively.

Clinical useEmployed to confirm unexpected presumptive results or when accurate, reliable identification/quantification is necessary for clinical decisions (e.g., SUD diagnosis/monitoring, opioid therapy management).

Relative characteristicsMore sensitive and specific than immunoassays but more labor- and time-intensive; considered gold-standard for identification.

inv-60: Forensic testing — definition and note that it's not addressed by policy

DefinitionForensic testing: drug testing conducted for legal proceedings that requires secondary confirmatory testing and chain-of-custody procedures.

Policy scope noteThis policy addresses clinical toxicology in outpatient settings and specifically does NOT address forensic testing.

inv-61: Definitive testing — chromatographic/spectroscopic methodologies (GC/LC with tandem MS) gold standard

Gold-standard methodsDefinitive testing uses chromatographic and spectroscopic methodologies (GC or LC with tandem MS) and is considered the gold standard for drug identification.

Recommended usesPreferred for baseline assessment and confirmation of unexpected results in chronic pain/opioid monitoring per consensus guidance.

TradeoffsHigher sensitivity/specificity but increased labor, time, and cost compared with immunoassays.

inv-62: Immunoassay / presumptive testing — rapid screening tests prone to cross-reactivity

DefinitionImmunoassay/presumptive testing: rapid qualitative screening tests (POC or lab-based) that typically detect drug classes rather than specific drugs and are subject to cross-reactivity.

Operational notePOC and laboratory immunoassays can offer similar performance characteristics but users must reference package inserts and consult labs for limitations, especially for amphetamines, benzodiazepines, and opiates.

LimitationsLower sensitivity and specificity vs LC‑MS/MS; may yield false positives/negatives and often require confirmatory definitive testing when results are unexpected or consequential.

inv-63: Definitive testing — lab methods such as GC-MS, LC-MS, LC-MS/MS for specific identification

Methods listedDefinitive laboratory methods include GC-MS, LC-MS, and LC-MS/MS used to specifically identify drugs and metabolites with higher sensitivity and specificity.

When to useUse to confirm presumptive positives that are inconsistent with history, to identify specific drugs within a class, or when concentrations are needed to guide management.

Regulatory/quality considerationsDefinitive assays typically require method- or drug-specific calibration and appropriate quality control materials to ensure accuracy.

inv-64: Point-of-care (POC) immunoassay — definition and limitations for in-office use

Definition and settingPoint-of-care (POC) immunoassay: rapid qualitative presumptive tests performed in-office or on POC analyzers to detect drug classes for immediate clinical screening.

AdvantagesFast, convenient, and can be cost-effective for detecting use or inappropriate use in clinical settings when interpreted correctly.

LimitationsPOC immunoassays share immunoassay limitations (cross-reactivity, variable sensitivity); clinicians must reference package inserts and consult labs and should obtain confirmatory definitive testing for unexpected or consequential results.

inv-65: Presumptive vs Definitive testing — summary comparison of modalities

Screen vs confirmPresumptive testing (immunoassay/POC) screens for drug classes; definitive testing (GC-MS/LC-MS/MS) confirms specific substances and quantifies when clinically necessary.

Clinical workflowInitial testing may be performed with immunoassay followed by definitive confirmation for unexpected or clinically impactful results.

Trade-offsPresumptive tests are faster and less costly but less specific; definitive tests are more accurate but resource-intensive—choose modality based on clinical need and payer/institutional policies.

inv-66: Adulterated specimen — definition and examples

DefinitionAdulterated specimen: a specimen altered by the patient as evidenced by abnormal constituents or concentrations (e.g., nitrite in urine) or characteristics suggesting tampering.

ExamplesAbnormal urine specific gravity, urine creatinine, abnormal pH, presence of oxidants or other adulterants indicate possible specimen tampering.

Policy implicationSpecimen validity testing (e.g., SG, creatinine, pH, oxidant level) is explicitly not covered per policy exclusions.

inv-67: Urine drug testing (UDT) — definition and scope

Definition and scopeUrine drug testing (UDT): laboratory testing of urine to detect the presence of psychoactive substances; can be presumptive (immunoassay) or definitive (chromatography/mass spectrometry).

Common specimenUrine is the most commonly used biological specimen for outpatient drug testing due to cost, noninvasiveness, and longer detection windows than blood or saliva.

Clinical applicationsUDT is used for treatment program compliance, monitoring opioid therapy, pregnancy/emergency assessment, SUD treatment, and transplant candidate evaluation when clinically indicated.

inv-68: Laboratory-developed tests (LDTs) — definition and regulatory context

DefinitionLaboratory-developed tests (LDTs): tests developed and validated by laboratories and regulated under CLIA as high-complexity tests; they are not FDA-approved but are permitted for clinical use.

Regulatory contextLDTs are regulated by CMS under CLIA '88 as high-complexity tests; FDA clearance/approval is not required for clinical use at present.

Policy noteLaboratories performing LDTs must validate and follow quality and calibration procedures consistent with definitive testing standards (e.g., MS-based methods) when used for clinical decisions.

inv-69: presumptive drug screening — additional definitional notes

Role as initial screenPresumptive drug screening typically refers to initial immunoassay-based tests used to screen specimens (e.g., urine) for presence of drugs or metabolites.

Susceptibility to errorThese screening assays are subject to false positives and false negatives and should be interpreted in clinical context and confirmed when unexpected.

Operational guidanceWhen using presumptive assays, clinicians should consult assay package inserts and laboratory experts to understand detection capabilities and cross-reactivity.

inv-70: definitive drug testing — additional definitional notes

Confirmation and specificityDefinitive drug testing (e.g., GC-MS, LC-MS/MS) provides specific identification and quantification and is recommended when results will guide major clinical decisions or when presumptive assays lack adequate detection.

Use in monitoringDefinitive testing is covered when specifically requested with documented rationale and when clinical criteria (e.g., SUD monitoring frequencies) are met for up to seven drug classes.

Analytic expectationDefinitive assays generally require method-specific calibration, matrix-matched QC, and stable-isotope/internal standards to ensure reliable results.

Background and Evidence Summary

Background: drug misuse is common, and urine is the most frequently used specimen for outpatient drug testing. This policy applies to outpatient clinical toxicology testing (primarily urine and oral fluid), addressing indications, specimen types, frequency limits, and testing practices; it does not apply to forensic testing or routine therapeutic drug monitoring outside the specified clinical contexts.

Policy Revision History and Changes

2025-03-05policy_revision

Reviewed and updated background, guidelines, recommendations, and evidence-based references; editorial clarifications made (removed former C and E in disclaimer, changed numerals to words for consistency); added new 'General' section CC6 establishing that presumptive drug screening and definitive drug testing do not meet coverage criteria in situations not otherwise addressed.

2024-09-04coding_updateLatest

Off-cycle coding modification added CPT codes 0517U, 0518U, 0519U, and 0520U (effective 2024-10-01) to the list of applicable procedure codes.